Highland Capital Management (Tennessee)’s United Therapeutics UTHR Stock Holding History

Highland Capital Management (Tennessee)’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-9,362	Closed	-$1.27M	–	388
2017 Q1	$1.27M	Sell	9,362 -2,322	-20%	-$352K	0.1%	174
2016 Q4	$1.68M	Buy	+11,684	New	+$1.49M	0.14%	149
2015 Q4	–	Sell	-4,978	Closed	-$653K	–	552
2015 Q3	$653K	Buy	4,978 +331	+7%	+$53.1K	0.05%	260
2015 Q2	$808K	Buy	+4,647	New	+$836K	0.06%	262

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Highland Capital Management (Tennessee)'s UTHR Position: Q2 2017 in Review

Highland Capital Management (Tennessee) sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 9,362 shares — an estimated $1.27M sold.

Highland Capital Management (Tennessee) first reported a position in UTHR in Q2 2015 and held it in 4 quarters. The position peaked at $1.68M in Q4 2016. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

Highland Capital Management (Tennessee) reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
Highland Capital Management (Tennessee) sold 9,362 United Therapeutics shares in Q2 2017, an estimated $1.27M.
Highland Capital Management (Tennessee) first reported a position in United Therapeutics in Q2 2015 and held it in 4 quarters.
Highland Capital Management (Tennessee)'s United Therapeutics position peaked at $1.68M in Q4 2016.
373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Highland Capital Management (Tennessee)'s 13F filing for Q2 2017, filed 19 Jul 2017.